Clinical Research Directory
Browse clinical research sites, groups, and studies.
CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer
Sponsor: Sohag University
Summary
This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and luminal B breast cancer. The study will assess how patients responded to these treatments based on their specific breast cancer subtype (Luminal A vs. Luminal B) by reviewing their medical records.
Official title: RETROSPECTIVE STUDY OF OUTCOME OF CDK4/6 INHIBITORS IN METASTATIC LUMINAL A AND LUMINAL B BREAST CANCER
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2021-01-01
Completion Date
2027-04-01
Last Updated
2026-07-15
Healthy Volunteers
No
Conditions
Interventions
CDK4/6 inhibitors
Retrospective evaluation of patients who received standard clinical doses of CDK4/6 inhibitors as part of their treatment regimen for metastatic luminal A and luminal B breast cancer.
Locations (1)
Sohag university hospital
Sohag, Egypt